Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Who’s to blame for the price Daraprim? It’s not who you think.

Brian C. Joondeph, MD
Meds
October 14, 2015
Share
Tweet
Share

Daraprim is a drug that no one ever heard of unless they are taking it. It is used to treat toxoplasmosis, a parasitic infection, has been around for decades, and is prescribed typically in patients with weakened immune systems, such as those with AIDS. Daraprim has been newsworthy because a small company, Turing Pharmaceuticals, recently purchased the drug from Impax Laboratories for $55 million, and promptly raised the price of Daraprim.

Originally $13.50 per pill, Turing raised the price to $750, sparking outrage over price gouging and taking advantage of sick patients. After the outcry, Turing will lower the price, but they have not disclosed by how much.

Is the Turing CEO a greedy businessman or an investor trying to recoup his investment and earn a profit? Should the free market determine drug prices or is there a role for government price controls?

Go back to 2003, the year Medicare Part D was created. Buried in the 1000+ page bill, which undoubtedly every member of Congress read and understood, was this dirty little secret: According to the law, Medicare itself is not allowed to negotiate drug prices with pharmaceutical companies. Was this known or debated at the time? The bill was rushed through Congress with a final vote at 3 a.m. How’s that for transparency?

Medicaid and Veterans Affairs are able to negotiate lower drug prices. As do foreign countries, which pay 50 percent less than we do for the same drugs. How could a bill like this pass through Congress? Easy. Lobbyists.

Credit former Congressman Billy Tauzin, R-La., for steering the bill through the House of Representatives, via arm twisting and a 3 a.m. vote. Rep. Tauzin was a long time Democrat, but he switched parties to maintain his seniority and power in Congress when Republicans took control in 1994. Eventually, he retired and became CEO of big pharma lobbying group PhRMA, earning a $2 million salary lobbying for the pharmaceutical industry. How’s that for a revolving door?

Passage of Medicare Part D more than paid for Mr. Tauzin’s salary. If Medicare had the same negotiating power as Medicaid, the Congressional Budget Office estimates, “It could save $116 billion over ten years,” money otherwise in the coffers of big pharma.

The argument is that pharmaceutical companies need profit for future research and development. That’s true. Bringing a new drug to market costs $2.5 billion. And takes 12 years on average with the odds of the new drug traveling from laboratory to pharmacy about 1 in 5,000. The counter argument is that most of the largest pharmaceutical companies spend more on marketing than on R&D. Meaning high drug prices are supporting TV commercials.

The result is that Medicare, and ultimately the taxpayers, pay whatever big pharma asks. That’s why medications used to treat macular degeneration cost $2,000 per month, consuming one-sixth of the Medicare Part B budget. For the patient with macular degeneration in both eyes, costs could reach $48,000 per year. Medicare happily pays the price set by big pharma. Other countries, on the other hand, negotiate prices down and pay approximately half of the U.S. cost.

Credit where credit is due. The Obama administration has asked Congress to authorize Medicare to directly negotiate with drug companies for some high-cost prescriptions. That will be a tough fight against the big pharma lobby.

Rather than focusing on a businessman buying a company and trying to make a profit, the attention should shift to the larger problem of Medicare’s non-negotiable prices, which everyone pays for through taxes and copays.

Brian C. Joondeph is an ophthalmologist and can be reached on Twitter @retinaldoctor. This article originally appeared in the Independent Journal.

Prev

Can we blame Martin Shkreli for succeeding in a system that we created?

October 14, 2015 Kevin 8
…
Next

Tips for patients to help ensure an accurate diagnosis

October 14, 2015 Kevin 114
…

ADVERTISEMENT

Tagged as: Medications

Post navigation

< Previous Post
Can we blame Martin Shkreli for succeeding in a system that we created?
Next Post >
Tips for patients to help ensure an accurate diagnosis

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Brian C. Joondeph, MD

  • Ophthalmology in the era of COVID-19

    Brian C. Joondeph, MD
  • An ophthalmologist analyzes Joe Biden’s red eye

    Brian C. Joondeph, MD
  • When medical science becomes fake news

    Brian C. Joondeph, MD

Related Posts

  • At the top of patients’ wish lists: price transparency

    Miranda Gill, MSN, RN
  • GOOP and Gwyneth: Blame mainstream media

    Arthur L. Caplan, PhD and Timothy Caulfield, LLM
  • Are generic drug price hikes media hype?

    Peter Ubel, MD
  • Drug price hikes sometimes have catastrophic effects on patients

    Zoe Tseng, MD and Suhas Gondi
  • Who’s really to blame for the obesity epidemic?

    Peter Ubel, MD
  • Blame the pain, not the opioids

    Angelika Byczkowski

More in Meds

  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • Most Popular

  • Past Week

    • 2 hours to decide my future: How the SOAP residency match traps future doctors

      Nicolette V. S. Sewall, MD, MPH | Education
    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • In a fractured world, Brian Wilson’s message still heals

      Arthur Lazarus, MD, MBA | Physician
    • When your dream job becomes a nightmare [PODCAST]

      The Podcast by KevinMD | Podcast
    • How doctors took back control from hospital executives

      Gene Uzawa Dorio, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
  • Recent Posts

    • When your dream job becomes a nightmare [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding healing in narrative medicine: When words replace silence

      Michele Luckenbaugh | Conditions
    • Why coaching is not a substitute for psychotherapy

      Maire Daugharty, MD | Conditions
    • When the white coats become gatekeepers: How a quiet cartel strangles America’s health

      Anonymous | Physician
    • Why doctors stay silent about preventable harm

      Jenny Shields, PhD | Conditions
    • Why interoperability is key to achieving the quintuple aim in health care

      Steven Lane, MD | Tech

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • 2 hours to decide my future: How the SOAP residency match traps future doctors

      Nicolette V. S. Sewall, MD, MPH | Education
    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • In a fractured world, Brian Wilson’s message still heals

      Arthur Lazarus, MD, MBA | Physician
    • When your dream job becomes a nightmare [PODCAST]

      The Podcast by KevinMD | Podcast
    • How doctors took back control from hospital executives

      Gene Uzawa Dorio, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
  • Recent Posts

    • When your dream job becomes a nightmare [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding healing in narrative medicine: When words replace silence

      Michele Luckenbaugh | Conditions
    • Why coaching is not a substitute for psychotherapy

      Maire Daugharty, MD | Conditions
    • When the white coats become gatekeepers: How a quiet cartel strangles America’s health

      Anonymous | Physician
    • Why doctors stay silent about preventable harm

      Jenny Shields, PhD | Conditions
    • Why interoperability is key to achieving the quintuple aim in health care

      Steven Lane, MD | Tech

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Who’s to blame for the price Daraprim? It’s not who you think.
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...